The UPS recognizes and targets (via ubiquitination) specific proteins for subsequent ATP-dependent degradation by the 26S proteasome. 5 Ubiquitination via the UPS machinery is a complex process that requires the concerted action of many different enzymes. 6 The essential 3 steps of the ubiquitylation cascade are ubiquitin activation via the enzyme E1, ubiquitin conjugation via one of multiple E2 enzymes, and ubiquitin ligation by one of >100 E3s. The latter are of particular importance because E3 ligases confer substrate specificity to the complex, thereby providing a mechanism for fine-tuning the equilibrium of synthesis and degradation for many specific proteins. 2, 7 Polyubiquitination involving the lysine 48 residue of ubiquitin typically results in proteasomal degradation of the ubiquitinated substrates (canonical pathway). However, it is well-recognized that monoubiquitination or noncanonical polyubiquitination of target proteins (eg, via lysine 63 of ubiquitin) serves important roles in intracellular signaling such as regulation of transcription or activation of kinases. 8, 9 The subgroup of E3 ligases that has been most widely characterized and that has been shown to be involved in a multitude of cellular functions is the S-phase kinase-associated protein 1 (Skp1)/Cul1/F-box (SCF) ubiquitin ligase complex, named for its principal components Skp1, Cullin, and an F-box protein. Within the SCF complex, F-box-containing proteins typically mediate substrate specificity via distinct protein-protein interaction domains and facilitate the transfer of ubiquitin from the respective E2 enzyme to the substrate, thereby determining its fate (degradation by the proteasome, altered signaling, or subcellular localization, and others). 10, 11 A number of E3 ligases have been identified to be striated muscle-enriched or even muscle-specific, including Atrogin-1, the muscle-specific RING finger protein (MuRF)-family, or carboxyl terminus of Hsp70-interacting protein. 7, 8, 12, 13 Interestingly, many of the currently known targets of muscleenriched E3 ligases are sarcomeric proteins, implying that the proper control of their quality as well as stochiometry is of critical importance for myocyte integrity and function. 1 However, little is known about additional components that constitute and regulate the UPS in cardiomyocytes. A deeper understanding of the specific components of the cardiac proteasome appears to be of particular interest, because several heart diseases recently have been shown to involve dysregulation of the UPS, also. 1, 5 Although the activity of the proteasome itself is not consistently downregulated in diseased hearts, 1, 14 several mouse models of cardiac hypertrophy and failure reveal significant alterations in the amount of ubiquitinated proteins and the expression levels of several E3 ligases, including atrogin-1, 7 MuRF1, 1, 9, 10 Mdm2, 2, 11 and carboxyl terminus of Hsp70-interacting protein. 8, 15 Similarly, various reports indicate that human cardiomyopathy (eg, desminopathy 16 or hypertrophic cardiomyopathy attributable to MyBP-C mutations 17 ) is associated with an increase of ubiquitinated cardiac proteins as well as malfunction of the cardiac UPS, resulting in the accumulation of misfolded or damaged proteins.
We report the first description of a previously uncharacterized cardiac-enriched F-box protein, termed F-box and leucine-rich protein 22 (Fbxl22) . Fbxl22 is a component of a novel bona fide SCF-E3 ligase, because it builds a complex with Skp1 and Cullin1 through its N-terminal F-box. Two important and abundant sarcomeric proteins, α-actinin-2 (ACTN) and filamin C (FLNC), were identified as substrates that are ubiquitinated in Fbxl22-dependent fashion. Consistently, overexpression of Fbxl22-facilitated proteasomal degradation of both ACTN and FLNC, whereas proteasome inhibition abrogated this effect. Conversely, targeted knockdown of Fbxl22 in zebrafish results in accumulation of α-actinin associated with severe contractile dysfunction and cardiomyopathy.
Methods
Detailed experimental procedures for cloning, bioinformatics, Northern blot analyses, Western blot analyses, immunofluorescence experiments, yeast 2-hybrid assays, tissue culture, immunoprecipitations, and reporter gene assays, as well as zebrafish injection procedures and fractional shortening measurements, are provided in the Online Data Supplement. Statistical analyses of the data were performed using ANOVA, followed by Student-Newman-Keuls post hoc tests. When appropriate, Student t test was used (2-sided, assuming similar variances). P<0.05 was considered statistically significant. The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the manuscript as written.
Results

Fbxl22 Is a Novel Cardiac-Enriched F-Box Protein
To identify novel sarcomeric cardiac-enriched genes, we searched the expressed sequence tag databases for previously uncharacterized sequences predominantly found in cardiac cDNA libraries. 14, 18 The data extraction mainly relied on the T-STAG (tissue-specific transcripts and genes) 19 and the Unigene (National Center for Biotechnology; http://www. ncbi.nlm.nih.gov/unigene) databases. Several of the newly identified expressed sequence tags corresponded to the human Unigene cluster Hs.656997 or the Mus musculus Unigene cluster Mm.297998. Expressed sequence tags in these clusters were significantly enriched for heart compared with other tissues (Online Figure IA) . Subsequent bioinformatic analyses revealed identity with a predicted protein termed Fbxl22 (National Center for Biotechnology Information reference sequences: human [NM_203373, NP_976307], mouse [NM_175206, NP_780415]). These sequences were used as templates for the design of primers for the amplification of the complete open reading frames, which predicted a novel 241 (human)/236 (mouse) amino acid protein with a calculated molecular weight of 27 kDa (human) and 26 kDa (mouse), respectively. Northern blot analyses in murine tissues showed a cardiac-specific expression pattern with only weak bands in uterus and skeletal muscle ( Figure 1A) . Similarly, quantitative reverse-transcriptase polymerase chain reaction conducted on
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S-phase kinase-associated protein 1 UPS ubiquitin-proteasome system samples of a human cDNA library confirmed cardiac-specific/ muscle-specific expression of Fbxl22 (Online Figure IB) . To next analyze the expression of Fbxl22 on the protein level, a Western blot of extracts from several mouse tissues was probed with a polyclonal antibody against Fbxl22. Again, a strong expression of Fbxl22 protein in mouse heart tissue at the predicted size of ≈26 kDa was observed ( Figure 1B ). Fbxl22 is conserved across several species ( Figure 1C ) and homology is highest in the N-terminal region of Fbxl22, where an F-box (AA 1-44) is located, a characteristic motif of proteins that form an SCF-E3 ligase complex and that mediate substrate specificity of the proteasome. 20 The F-box-containing, highly conserved N-terminal part of the molecule exhibits a striking enrichment of leucine residues in all species (≈20% of all amino acids), whereas the C-terminal part of the protein sequence is less conserved and contains several regions of low complexity ( Figure 1C and 1D).
Fbxl22 Is Located at the Cardiac Z-Disc
Having shown a high expression level of Fbxl22 in the myocardium, we next aimed to determine its subcellular A faint signal is also detected in uterus. Fbxl22 is detected at ≈1.6 kb (ladder in kb). B, Immunoblot of adult murine tissues with anti-Fbxl22 confirms predominant cardiac expression of Fbxl22 at ≈26 kDa. Bottom, Normalization with tubulin. C, Alignment of Fbxl22 sequences from several different species: homo sapiens, mus musculus, rattus norvegicus, bos Taurus, and danio rerio. The N terminus of Fbxl22 (AA1-113), which contains the F-box (AA1-44), is highly conserved across species, whereas the C terminus is less well-conserved. Identical amino acids are highlighted with darker shades of blue, and black bars below indicate the consensus sequence. D, Schematic structure of human Fbxl22 revealing the F-box motif (yellow) located in its highly conserved N-terminal part and exhibiting an aggregation of numerous leucine residues (19% of all amino acids). The less conserved C-terminal part of Fbxl22 contains several regions of low complexity (denoted in pink). localization by using immunostaining experiments. Staining of cultivated neonatal rat ventricular cardiomyocytes with anti-Fbxl22 and anti-calsarcin-1 antibodies 21 revealed colocalization of both proteins at the level of the sarcomeric z-disc ( Figure 2A ). Likewise, immunostaining of isolated adult rat ventricular cardiomyocytes with anti-calsarcin-1 and anti-Fbxl22 confirmed a z-disc localization for Fbxl22 ( Figure  2B , Online Figure II) . Consistently, cryosections of intact murine heart again showed a z-disc specific signal ( Figure 2C , Online Figure II) , consistent with the notion that Fbxl22 is a component of the sarcomere.
Fbxl22 Is a Novel Member of the Cardiac UPS
Fbxl22 contains the F-box domain, which implies a role in the ubiquitin-proteasome machinery. Specifically, Fbxl22 may be a component of a novel cardiac-specific SCF-E3 ligase complex. To identify potential protein interaction partners, we performed a yeast 2-hybrid screen using Fbxl22 as bait ( Figure 3A ). Screening of a human cardiac cDNA library yielded 2 clones of Skp1, a well-characterized part of the SCF machinery known to interact with the F-box motif of several F-box proteins. 22 To confirm this interaction in mammalian cells, human embryonic kidney (HEK)293 cells were transfected with hemagglutinin-tagged Fbxl22 and Myctagged Skp1. As shown in Figure 3C , coimmunoprecipitation studies confirmed a strong interaction of the 2 proteins. Moreover, the precipitated protein complex also contained endogenous Cullin1, another critical component of the SCF-E3 ligase machinery ( Figure 3C ). To also confirm this interaction in cardiomyocytes, we repeated this experiment with adenovirally overexpressed Fbxl22 in neonatal rat ventricular cardiomyocytes. Again, endogenous Skp1 could be coimmunoprecipitated by Fbxl22 ( Figure 3D ).
Fbxl22 Directly Interacts With ACTN and FLNC
The yeast 2-hybrid screen also yielded 2 sarcomeric proteins, α-actinin and FLNC ( Figure 3A ), which are known to be located at the cardiac Z-disc, consistent with the subcellular Figure 2 . F-box and leucine-rich repeat protein 22 (Fbxl22) is localized to the sarcomeric z-disc in neonatal and adult cardiomyocytes. A, Subcellular localization of Fbxl22 in neonatal rat ventricular cardiomyocytes (NRVCM). Staining of NRVCM with a Fbxl22 antibody (fluorescein isothiocyanate-green) reveals a strong signal at the sarcomeric z-disc, validated by colocalization with the known z-disc protein calsarcin-1 (Cy3-red). Scale bar, 5 μm. B, Subcellular localization of Fbxl22 in adult rat ventricular cardiomyocytes (ARVCM), which were stained with antibodies against Fbxl22 (green) and calsarcin-1 (red). When signals are merged, a colocalization at the sarcomeric z-disc is observed. Scale bar, 5 μm. C, Subcellular localization of Fbxl22 in the intact murine heart. Heart sections were stained with antibodies against Fbxl22 (green) and calsarcin-1 (red). Again, Fbxl22 was found to localize to the z-disc, confirming its subcellular localization in cardiac tissue. Scale bar, 5 μm. December 7, 2012 localization of Fbxl22. In accordance with the interacting domains ( Figure 3B ), we engineered epitope-tagged expression constructs of ACTN and the C-terminal part of FLNC, respectively, and cotransfected these with Fbxl22. Subsequent coimmunoprecipitation and Western blot analyses validated the interactions of Fbxl22 with both ACTN and FLNC ( Figure 3E and 3F). Consistently, confocal microscopy reveals colocalization of Fbxl22 with FLNC at the z-disc of isolated cardiomyocytes (Online Figure III) . Because sequence analyses of Fbxl22 ( Figure 1C and 1D) had revealed that its N terminus is highly conserved across different species, we speculated that this part of the protein might confer the interaction with the identified binding partners. Therefore, an expression construct encoding for the 113 aminoterminal amino Figure 3 . F-box and leucine-rich repeat protein 22 (Fbxl22) is a novel member of the cardiac ubiquitin-proteasome system and directly interacts with S-phase kinase-associated protein 1 (Skp1), α-actinin-2 (ACTN) and filamin C. A, A yeast 2-hybrid screen with Fbxl22 as bait identifies Skp1 as well as ACTN and filamin C as protein interaction partners. B, Analyses of several yeast clones map the interaction domain to the C terminus of ACTN and filamin C, respectively. The fragment of ACTN sufficient for interaction with Fbxl22 comprises 570 amino acids (AA 325-895) and exhibits spectrin domains (blue) and repeats (purple), as well as EF-hand motifs (green). The part of filamin C responsible for the interaction with Fbxl22 was mapped to the C-terminus of Filamin C (FLNC; AA 2384-2724) and contains the last 3 filamin-type [22] [23] [24] acids was cloned and, again, HEK293 cells were transfected to perform coimmunoprecipitation experiments. This construct was sufficient to mediate the interaction with endogenous Skp1 (Online Figure IVA) , consistent with the known role of F-box domains to bind to this component of the E3 ligase complex. Similarly, the N terminus of Fbxl22 strongly precipitated αactinin (Online Figure IVB) and FLNC (Online Figure IVC ), suggesting that these interactions also are mediated by the F-box containing and leucine-rich part of Fbxl22.
Next, we asked whether these interactions also occur in cardiomyocytes. We therefore performed a similar experiment with adenovirally overexpressed Fbxl22 in neonatal rat ventricular cardiomyocytes. Consistently, endogenous α-actinin could be coimmunoprecipitated by Fbxl22 ( Figure 3G ).
Fbxl22 Facilitates Degradation of ACTN and FLNC
After the identification of several sarcomeric proteins as binding partners for Fbxl22, we sought to investigate the potential function of these interactions and in which cellular processes Fbxl22 might be involved. Specifically, ACTN and FLNC might represent substrates for Fbxl22, because F-box proteins have been shown to target proteins to the proteasome. 23, 24 Thus, HEK293 cells were cotransfected with plasmids encoding for Fbxl22 and ACTN or FLNC, respectively. Western blot analyses confirmed a marked dose-dependent decrease of ACTN levels in the presence of Fbxl22 ( Figure 4A ). As shown in Figure 4B , densitometric analyses of several experiments (n=3) revealed a highly significant reduction of ACTN levels by 65% (±16% SEM; P<0.01). Similarly, cotransfection of FLNC and Fbxl22 again led to a significant decrease of filamin C ( Figure 4C ). Densitometric analysis revealed a 66% reduction of filamin levels in the presence of Fbxl22 (±12% SEM; P<0.001; Figure 4D ).
Next, we investigated whether the same mechanism also is operative in cardiomyocytes. Again, upregulation of Fbxl22 resulted in significant downregulation of endogenous α-actinin expression. Conversely, targeted knockdown of Fbxl22 using a synthetic adenovirally encoded microRNA led to accumulation of α-actinin in cardiomyocytes ( Figure 4G and 4H ). Of note, ACTN and FLNC mRNA levels were not significantly altered by Fbxl22 overexpression (Online Figure V) . Taken together, these data suggest that Fbxl22 is sufficient to facilitate the degradation of at least 2 sarcomeric proteins, ACTN and FLNC, whereas its downregulation results in accumulation of its targets.
Fbxl22-Mediated Degradation of ACTN and FLNC Is Proteasome-Dependent
Proteasomal inhibition repeatedly has been demonstrated to attenuate SCF-mediated degradation of specific substrates. [25] [26] [27] To provide further evidence of Fbxl22-facilitated proteasome-dependent degradation of ACTN and FLNC, we used the proteasome inhibitor MG-132 and repeated the experiments described. MG-132 completely prevented Fbxl22mediated degradation of both ACTN ( Figure 5A ) and FLNC ( Figure 5B ), implying that Fbxl22 functions as a bona fide SCF-E3 ligase that mediates the proteasomal degradation of its sarcomeric substrates.
Fbxl22 Promotes Ubiquitination of ACTN and FLNC
Because SCF ligases are known to determine the fate of their respective substrates (eg, degradation, signaling) by specific ubiquitination, 23 we hypothesized that the observed increased proteasomal degradation of ACTN and FLNC is associated with Fbxl22-mediated ubiquitination of these substrates. To validate this concept of ubiquitin-driven substrate degradation and to assess whether Fbxl22 and its associated proteins (Skp1, Cullin1) truly function as SCF-E3 ligase, we performed ubiquitination experiments.
Thus, HEK293 cells were transfected with plasmids encoding for Fbxl22, ubiquitin, and myc-tagged ACTN ( Figure 6 ). In an in vitro ubiquitination assay, lysates from these cells then were incubated with ubiquitination buffer (containing MG-132, ubiquitin-aldehyde, dithiothreitol, and ATP) and incubated for 30 minutes at 37°C. Immunoblotting revealed a slurry of slower migrating, ubiquitinated ACTN in the presence of Fbxl22, which could be further enhanced by addition of ubiquitin ( Figure 6A) . Similarly, proteasomeinhibited HEK293 cells were transfected with plasmids encoding for Fbxl22, ubiquitin, and α-actinin or FLNC, respectively. Immunoprecipitation with Fbxl22 resulted in a marked increase in the amount of ubiquitinated substrates ( Figure 6B and 6C ), in line with the notion that Fbxl22 is an essential component of a novel cardiac-specific SCF-E3 ligase. Finally, cells again were transfected with Fbxl22 and Myc-tagged ACTN (but without additional ubiquitin), and were subjected to treatment with MG-132 or control (Online Figure VI) . Fbxl22-facilitated degradation of ACTN (Online Figure VI, upper panel, lanes 1-2) , whereas proteasome inhibition by MG-132 significantly attenuates this Fbxl22-dependent effect ( Figure 5D, upper panel, lanes 3-4) . Interestingly, ubiquitin precipitates of ACTN only accumulate in the presence of the proteasome inhibitor (Online Figure VI, lower panel, lane 4) . To exclude an unspecific effect of Fbxl22 on ubiquitination, we assayed global ubiquitination levels in Fbxl22-depleted cardiomyocytes (neonatal rat ventricular cardiomyocytes) under starving conditions and in a growth-stimulated environment. Neither experiment showed a differential effect, consistent with the notion that Fbxl22 does not influence total ubiquitination (Online Figure VII) . Taken together, these ubiquitination studies confirm a dose-dependent increase in Fbxl22-dependent ubiquitination and subsequent degradation of the specific substrates ACTN and FLNC.
Fbxl22 Is Downregulated on Cardiomyocyte Stress
Next, we asked whether the expression level of Fbxl22 is differentially regulated under conditions of cardiomyocyte stress. Therefore, we first subjected neonatal rat cardiomyocytes to phenylephrine treatment, a potent inducer of hypertrophy and the fetal gene program ( Figure 7A ). Phenylephrine was sufficient to strongly induce atrial natriuretic factor expression (30.6×; P<0.001 versus control). In contrast, Fbxl22 was found to be significantly downregulated (0.23×; P<0.001 versus control). Similarly, analysis of mouse hearts subjected to pressure overload attributable to transverse aortic constriction revealed induction of atrial natriuretic factor (3.3×; P<0.01 versus control), whereas Fbxl22 expression was again repressed (0.58×; P<0.001 versus control). Thus, Fbxl22 expression is subject to differential regulation on pharmacological and biomechanical stress, both in vitro and in vivo.
Knockdown of Fbxl22 Leads to Progressive Reduction of Cardiac Contractility In Vivo
To investigate the role of Fbxl22 in vivo, we inactivated zebrafish fbxl22 by injecting morpholino (MO)-modified antisense oligonucleotides directed against the translational start site (MO-fbxl22) into 1-cell-stage zebrafish embryos ( Figure 8A ). When injected with 2 ng of MO-fbxl22, 91.8 ± 1.3 % of injected embryos (n=505; P<0.001; Figure 8B ) had development of severely reduced cardiac contractility accompanied by signs of heart failure, such as pericardial edema ( Figure 8A , Online Movie I), whereas cardiac performance of embryos injected with a standard MO-control was unaffected (n=101; Figure  8A , Online Movie II). To confirm that the fbxl22 morphant heart contractility phenotype is specific to the loss of fbxl22 function, we injected a second independent MO-modified antisense oligonucleotide directed against the splice donor site of exon 1 (MO2-fbxl22) of zebrafish fbxl22 into 1-cellstage zebrafish embryos. Injection of 0.4 ng of MO2-fbxl22 leads to identical phenotypic characteristics compared with MO-fbxl22 morphant zebrafish embryos (90.8 ± 0.8 %, n=424; P<0.001; Online Figure VIII ), confirming specificity of the observed fbxl22 morphant heart failure phenotype. To quantify this observation, we assessed fractional shortening of the ventricular chamber in Fbxl22 morphant embryos at 48 and 72 hours postfertilization (hpf). As in embryos injected with MO-control, the 2 heart chambers-atrium and ventricle-contract rhythmically, sequentially, and vigorously in Fbxl22 morphant embryos by 36 hours of fertilization (hpf; data not shown). However, by 48 hpf, fractional shortening of embryos injected with MO-fbxl22 decreases progressively (MO-fbxl22: 26.3 ± 15.6% versus MO-control: 46.2 ± 4.8%) and becomes almost completely lost at 72 hpf (MO-fbxl22: 2.3 ± 3.3% versus MO-control: 49.3 ± 6.9%; Figure 8B , right panel, and Online Movie III). To determine whether the heart of the Fbxl22 morphant contractile dysfunction defect is attributable to abnormal cardiac chamber development and morphogenesis, we next analyzed Fbxl22 morphant hearts on the structural and molecular levels. As shown by histological analyses, embryonic heart morphogenesis proceeds normally in MO-fbxl22 injected zebrafish. By 72 hpf, Fbxl22 morphant heart chambers are structurally indistinguishable from control hearts. Myocardial and endocardial cell layers are properly developed, and also the atrioventricular canal including endocardial cushions cells is correctly formed in Fbxl22 morphant hearts ( Figure 8C ). As revealed by whole-mount antisense RNA in situ hybridization, cardiac chambers are properly demarcated and ventricular, and atrial cardiomyocytes are regularly differentiated. The expression of cardiac-specific genes such as the cardiac myosin light chain 2 and chamberspecific myosin heavy chains (vmhc, amhc) were found to be expressed in the typical heart chamber-restricted pattern and in normal amounts (Online Figure IX) . Moreover, expression of atrial natriuretic factor also was unaffected by the loss of Fbxl22 function in the zebrafish embryo. These findings indicate that Fbxl22 is dispensable for early heart development and cardiomyocyte differentiation, as observed in several other zebrafish heart failure mutants. 14, 18, 28 Interestingly, in addition to their cardiac phenotype, Fbxl22 morphants display severe impairment of skeletal muscle function. When touchstimulated, embryos injected with MO-fbxl22 were unable to execute a flight response in contrast to control embryos (Online Movie IV). To next assess whether impaired heart and skeletal muscle function in Fbxl22-deficient zebrafish embryos is attributable to a disturbed cytoarchitecture, we analyzed their (ultra)structure by immunofluorescence and transmission electron microscopy. Of note, at 48 hpf, embryos injected with MO-fbxl22 are devoid of ultrastructural abnormalities. Arrays of thick and thin myofilaments as well as z-discs appear unaltered in Fbxl22 morphant muscles (Online Figure X) .
Finally, because we found Fbxl22 to specifically interact with α-actinin and to promote its proteasomal degradation, we investigated whether loss of Fbxl22 in zebrafish leads to the accumulation of α-actinin. Western blot analyses reveal that knockdown of Fbxl22 leads to a marked increase of α-actinin protein levels (2.5-fold upregulation; n=45 pooled embryos; Figure 8D ), substantiating our previous findings in mammalian cells. To further confirm this finding, we next performed Fbxl22-knockdown experiments followed by incubation of the injected embryos with the proteasome inhibitor MG-132. As hypothesized, we observed a further enhanced accumulation of α-actinin in MG132-treated embryos compared with controls (3.7-fold upregulation; n=52 pooled embryos; Figure 8D ). In contrast, several other potential target proteins such as myosin, cadherin, α-actin, or tropomyosin did not reveal an upregulation on knockdown of Fbxl22 ( Figure 8E ), suggesting that Fbxl22 promotes degradation of target proteins in a selective fashion.
Discussion
Here, we provide the detailed molecular and functional characterization of a previously uncharacterized cardiac-enriched F-box protein, termed Fbxl22.
The F-box protein motif, a (loosely) conserved 40-amino acid sequence, initially has been identified in cyclin F, where it is required for the interaction with Skp1 and subsequent proteasome-dependent cyclin degradation. 22 In subsequent studies, the F-box hypothesis has been confirmed and extended to multiple other proteins. 20, 29 In this concept, F-box-containing proteins are essential elements of the UPS, conferring substrate specificity to ubiquitin ligation. Consistently, we show that Fbxl22 also forms a complex with Skp1 and cullin, the principal components of an SCF-E3 ubiquitin ligase. Moreover, overexpression of Fbxl22 led to a dose-dependent ubiquitination and proteasomal degradation of its newly identified targets, ACTN and FLNC. Conversely, proteasome inhibition with MG-132 markedly blunted these effects, again consistent with the notion that Fbxl22 is a novel component of a bona fide cardiac E3 ligase.
Similar to other tissues, the UPS increasingly has been recognized as a key mechanism in the control of protein turnover in the heart. 5, 30 Yet, only a few other striated muscle-specific E3 ligases have been identified to date, including atrogin-1/ muscle atrophy F-box, 7, 31 the MuRF protein family members, 13 carboxyl terminus of Hsp70-interacting protein, 32 and ozz. 33 Of these, only the MuRFs and, in particular, MuRF-1 also have been shown to target important sarcomeric proteins such as myosin-binding protein C and the myosin heavy chains. 25, 34 Like Fbxl22, MuRF3 also targets the muscle-specific filamin isoform, FLNC, 35 suggesting a potential redundancy in the control of the intracellular levels of this essential muscle protein. The tight control of FLNC levels is further underscored by the existence of a ubiquitin-specific protease 25, which has been shown to deubiquitinate filamin. 36 In contrast, no other E3 ligase so far has been shown to mediate degradation of ACTN, which is another key component of the sarcomere, and especially of the sarcomeric z-disc. Fbxl22 is an attractive candidate in this regard because we could show that it not only facilitates actinin degradation but also is localized at the sarcomeric z-disc. Remarkably, most other muscle E3 ligases also have been shown to localize to the z-disc (atrogin-1, MuRFs, TRIM32), consistent with the emerging concept that this structure is a nodal point in intracellular signaling. 37, 38 In this regard, the UPS has been demonstrated not only to control turnover of key proteins in the heart and skeletal muscle but also to participate in diverse signaling pathways. For example, atrogin-1 has been ascribed an important role in regulating the phosphatase calcineurin as well as forkhead proteins such as FoxO3, which in turn modify hypertrophic signaling. 29, 39 Similarly, the UPS regulates apoptosis via mdm2/carboxyl terminus of Hsp70-interacting proteindependent degradation of p53. 3 In skeletal muscle tissue, muscle atrophy is controlled by upregulation of the E3 ubiquitin ligases atrogin-1 and MuRF1. 12 Conversely, muscle-specific ring finger 1-deficient mice are resistant to both skeletal muscle and cardiac atrophy. 9, 12, 25 Recently, the UPS also has been linked to human cardiomyopathy and heart failure. In most studies, failing hearts reveal an accumulation of ubiquitinated proteins, implying a general increase in proteasome activity. 40, 41 Moreover, impairment of the UPS has been linked to contractile dysfunction in experimental mouse models. 42 Likewise, a general decrease in F-box proteins attributable to downregulation of CSN (COP9 signalosome) results in cardiac hypertrophy and severe heart failure. 43 Moreover, many individual components of the UPS, including several E3 ligases, have been shown to be dysregulated in heart failure. 27, [44] [45] [46] For example, atrogin-1 is upregulated in doxorubicin-induced cardiomyopathy, 46 and both atrogin-1 and MuRF-1 are induced in experimental ischemic cardiomyopathy. 44 Furthermore MuRF-1 and atrogin-1 have been implicated in hypertrophic cardiomyopathy, because both E3 ligases mediate the decay of truncated mutant myosin-binding protein C. 27 Moreover, marked UPS dysfunction also has been demonstrated in desmin-related cardiomyopathy. 45 Of note, both newly identified targets for Fbxl22-dependent degradation, ACTN and FLNC have been linked to the pathogenesis of inherited cardiac and skeletal muscle diseases. ACTN has been shown to be a disease-causing gene for both dilated 47 and hypertrophic cardiomyopathy, 48 supporting the view of actinin as a key z-disc protein in the maintenance of cardiac integrity and function. Similarly, FLNC as the other Fbxl22 target identified in our study has been demonstrated to be a disease gene for myofibrillar myopathy. This striated muscle disease, predominantly affecting skeletal muscle but also the heart, is characterized by an accumulation of a mutated sarcomeric protein, typically proteins associated with zdisc such as FLNC, ZASP, or desmin. 49 Thus, it is tempting to speculate that myofibrillar myopathy-associated filamin mutations may alter its Fbxl22-dependent degradation.
A potential role of Fbxl22 in cardiac diseases in general and cardiomyopathy in particular is supported by our finding that targeted ablation of Fbxl22 in zebrafish leads to considerable accumulation of α-actinin associated with severe contractile dysfunction in vivo. However, we could not detect actinin aggregates in zebrafish or cardiomyocytes on downregulation of Fbxl22 by immunofluorescence or electrone microscopy. Thus, the exact mechanism responsible for cardiomyopathy in Fbxl22-knockdown zebrafish still remains unclear. It is conceivable that other potential mechanisms beyond mere (toxic) cellular accumulation of actinin and filamin may play a role, (eg, the upregulation of other still unknown Fbxl22 targets). Of note, despite the downregulation of Fbxl22, cardiomyocyte architecture as well as maturation were largely intact, suggesting that the observed cardiomyopathy is not merely secondary to structural alterations. Moreover, it remains to be established whether the accumulation of α-actinin is merely associated with cardiomyopathy or if a true causal relationship exists.
Finally, we found Fbxl22 markedly downregulated on cardiomyocyte stress, both in vitro and in vivo. Thus, it will be interesting to explore whether differential regulation of Fbxl22 is required for the stress response of cardiomyocyte and development of hypertrophy. Interestingly, small hairpin-RNAmediated downregulation of FLNC inhibits cardiomyocyte hypertrophy. 50 It is therefore conceivable that upregulation of FLNC and other key sarcomeric proteins is necessary for cardiomyocyte hypertrophy. Nevertheless, our current data cannot definitely answer these questions. Gain-of-function and loss-of-function experiments under conditions of increased cardiac stress will be required to ultimately define the role of Fbxl22 in vivo and, in particular, in cardiac disease.
In summary, we characterized a novel cardiac-specific F-box protein termed Fbxl22, which recruits 2 important sarcomeric z-disc proteins, ACTN and FLNC, for UPS-dependent degradation. Downregulation of Fbxl22 in vitro and in vivo results in a dysbalance of myocardial α-actinin content and impairment of contractile function. 50 Additional in vivo experiments as well as analyses of Fbxl22 in patient samples will help to clarify whether this novel cardiac E3 ligase also participates in cardiac signaling pathways and the pathogenesis of cardiomyopathy.
